Phase I/II Study of Avelumab in Pediatric Cancer Participants

Inclusion Criteria

• •Male or female subjects 0 to less than 18 years of age at the time of first treatment dose with histologically or cytologically confirmed solid malignant tumors (including CNS tumors) or lymphoma for which no standard therapy is available
• •Confirmed progression on or refractory to standard therapy or no standard therapy available.
• •Availability of archival formalin-fixed, paraffin-embedded block containing tumor tissue, or slides, or a fresh/recent tumor biopsy prior to avelumab treatment for subjects in Phase 2
• •Adequate bone marrow, kidney, and liver function